Cabio Biotech (Wuhan) Co (SHSE:688089) LT-Debt-to-Total-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cabio Biotech (Wuhan) Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.01.

Cabio Biotech (Wuhan) Co's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Sep. 2024 (0.01). It may suggest that Cabio Biotech (Wuhan) Co is progressively becoming more dependent on debt to grow their business.

Cabio Biotech (Wuhan) Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co LT-Debt-to-Total-Asset Chart

Cabio Biotech (Wuhan) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Cabio Biotech (Wuhan) Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	0.01

Cabio Biotech (Wuhan) Co LT-Debt-to-Total-Asset Calculation

Cabio Biotech (Wuhan) Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.662	/	1611.493
	=	0.00

Cabio Biotech (Wuhan) Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	11.532	/	1664.594
	=	0.01

Cabio Biotech (Wuhan) Co (SHSE:688089) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cabio Biotech (Wuhan) Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cabio Biotech (Wuhan) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 999, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, CHN, 430073

Website

http://www.cabio.cn

Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.

Executives

Xiao Min	senior management
Shang Yun	Core technical personnel
Wang Hua Biao	Directors, senior managers
Geng An Feng	senior management
Du Bin	Director
Yi Hua Rong	senior management
Ma Tao	senior management
Li Xiang Yu	senior management
Wu Yu Jun	Supervisors
Wang Zhi Ming	senior management
Lu Shu Huan	Core technical personnel
Yi De Wei	Director

Cabio Biotech (Wuhan) Co Headlines

No Headlines